



HEALTH SYSTEMS LAW AND POLICY CASES AND MATERIALS

VOLUME II

Colleen M. Flood

January-April 2004

**Faculty of Law
University of Toronto**

These materials are not to be regarded as published. They have been reproduced for the exclusive use of students in the Faculty of Law, University of Toronto and for use as a classroom teaching tool.

HEALTH SYSTEMS LAW AND POLICY CASES AND MATERIALS


VOLUME II

Colleen M. Flood

January-April 2004

**Faculty of Law
University of Toronto**

These materials are not to be regarded as published. They have been reproduced for the exclusive use of students in the Faculty of Law, University of Toronto and for use as a classroom teaching tool.



Digitized by the Internet Archive
in 2018 with funding from
University of Toronto

March 9th

Chapter Eight

ACCESS TO AND THE PRICING OF PRESCRIPTION DRUGS

R. G. Elgie, “Regulating Prices of Patented Pharmaceuticals in Canada: The Patented Medicine Prices Review Board” (May 1996) 13: 2 Food, Drug, Cosmetic and Medical Device Law Digest 80--83.VIII, 1-9

M. Shuchman, “Drug firm threatens suit over M.D.’s product review,” *Globe and Mail*, Wed., Nov. 17, 1999.VIII, 10-12

S. Jacobzone, "Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals (OECD Report: 2000).....VIII, 13-36

Commission on the Future of Health Care in Canada, *Building on Values: The Future of Health Care in Canada*, Final Report, November 2002, Chapter 9 (pp189—201).....VIII, 37-58

Daniel S. Greenberg, Medicare Reforms Receive Mixed Reaction, (2003) 362 *The Lancet* 1990.....VIII -59

Drew D. Altman, The New Medicare Prescription-Drug Legislation (2004) 350; 1 *N Engl. J. Med.* 9.....VIII, 60-61

M. M. Mellow, D. M. Studdert, and T. A. Brennan, “The Pharmaceutical Industry versus Medicaid – Limits on State Initiatives to Control Prescription-Drug Costs....VIII, 61-67

